Modality
Radioligand
MOA
STINGag
Target
CD38
Pathway
Proteasome
FLSCLC
Development Pipeline
Preclinical
~Sep 2021
→ ~Dec 2022
Phase 1
Mar 2023
→ Dec 2025
Phase 1Current
NCT08886933
2,816 pts·FL
2023-03→2025-12·Not yet recruiting
2,816 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-283mo agoInterim· FL
2026-10-056mo awayPh1 Dose Esc· SCLC
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2025-12-28 · 3mo ago
FL
Ph1 Dose Esc
2026-10-05 · 6mo away
SCLC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08886933 | Phase 1 | FL | Not yet recr... | 2816 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |